Abstract
Diabetic retinopathy (DR) comprises a major challenge to the public health and economy, being the leading cause of vision loss in working-aged adults in developed countries. If left untreated, DR will eventually progress leading to devastating blinding consequences including diabetic macular edema (DME), vitreous hemorrhage and tractional retinal detachment. Ranibizumab is a humanized monoclonal antibody fragment that targets the vascular endothelial growth factor (VEGF). It has been approved by the US FDA for the treatment of DME and DR in patients with DME. Given its proven efficacy and favorable safety profile, it has been widely used as one of the preferred therapeutic option for DME in modern clinical practice. This review provides a comprehensive overview on the safety and efficacy of ranibizumab in the management of DR and its associated sight-threatening microvascular complications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 329-340 |
| Number of pages | 12 |
| Journal | Expert Review of Ophthalmology |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2015 |
Keywords
- Ranibizumab
- intravitreal injection
- laser photocoagulation
- macular edema
- monoclonal antibodies. neovascularization
- retinopathy severity
- vascular endothelial growth factor
- vitreous hemorrhage
ASJC Scopus subject areas
- Biomedical Engineering
- Ophthalmology
- Optometry